- $835.58m
- $339.18m
- $7.87m
Annual balance sheet for Nuvation Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 216 | 765 | 661 | 611 | 503 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.09 | 3.04 | 2.48 | 3.7 | 16.3 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 221 | 772 | 667 | 616 | 526 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.688 | 3.66 | 4.68 | 4.32 | 2.99 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 222 | 776 | 672 | 621 | 541 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 6.55 | 16.9 | 13.2 | 14 | 58.2 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 6.71 | 30.2 | 17.1 | 16.4 | 76.8 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 215 | 746 | 655 | 605 | 464 |
Total Liabilities & Shareholders' Equity | 222 | 776 | 672 | 621 | 541 |
Total Common Shares Outstanding |